Moderna Closes $3B Convertible Notes Offering at 47.5% Premium
MRNA has more than doubled off its 52-week low of $22.28.
Summary
A $3.0B convertible notes offering was completed at a 47.5% conversion premium, with capped calls to limit dilution. Net proceeds of ~$2.96B will fund oncology growth and debt repayment.
Key Events · Financing and Capital Events · MRNA
-
$3B Convertible Notes Offering Completed
The upsized $3.0B 0% convertible senior notes offering due 2032 has been closed, including full exercise of the $400M additional purchase option.
-
Conversion Premium of 47.5%
The initial conversion price of $210.58 per share represents a 47.5% premium over the $142.77 last reported sale price on August 27, 2026.
-
Net Proceeds of $2.96B
Net proceeds were approximately $2,957.3M after fees, with $328.8M used for capped call transactions. Remaining funds are earmarked for oncology growth and debt repayment.
-
Capped Calls Limit Dilution
Capped call transactions with a cap price of $392.62 (175% premium) are expected to reduce potential dilution upon conversion.
Analysis · MRNA · Life Sciences
A $3.0 billion 0% convertible senior notes offering due 2032 has been completed, upsized from the initially proposed $2.0 billion. The notes convert at $210.58 per share, a 47.5% premium to the $142.77 reference price on August 27, 2026. Net proceeds of approximately $2.96 billion will fund oncology growth and debt repayment. To reduce potential dilution upon conversion, the company also entered capped call transactions with a cap price of $392.62. This substantial capital raise strengthens the balance sheet but introduces potential future dilution of up to 21 million shares if fully converted.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 30% of the 1972 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRNA was trading at $152.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $61.6B. The 52-week trading range was $22.28 to $176.66. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.